These pre-clinical data have encouraged clinical trials targeting PD-1 and PD-L1, either as monotherapy or in combination with radiation or chemotherapy, in pancreatic cancer (Table 1, current active clinical trials, and Table 2, past clinical trials targeting pancreatic cancer TME). This evidence concerns the gene CD274 and familial pancreatic carcinoma.